| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
52,373,000 |
| Market
Cap: |
2.52(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$30.85 - $52.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 474 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vericel is a biopharmaceutical company providing cell therapies for the sports medicine and severe burn care markets. Co.'s products include: MACI®, which is an autologous cellularized scaffold product indicated for the repair of symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults; and Epicel®, which is a permanent skin replacement for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area. Co. also holds a license for North American rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
134,738 |
259,234 |
263,234 |
303,833 |
| Total Sell Value |
$6,189,261 |
$10,761,080 |
$10,907,920 |
$12,010,179 |
| Total People Sold |
5 |
7 |
7 |
7 |
| Total Sell Transactions |
12 |
29 |
31 |
34 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Halpin Michael |
Chief Operating Officer |
• – – |
2021-02-11 |
4 |
D |
$49.23 |
$74,633 |
D/D |
(1,516) |
5,437 |
|
- |
|
| Halpin Michael |
Chief Operating Officer |
• – – |
2021-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,500 |
6,953 |
|
- |
|
| Hopper Jonathan Mark |
Chief Medical Officer |
• – – |
2021-02-11 |
4 |
D |
$49.23 |
$36,332 |
D/D |
(738) |
24,633 |
|
- |
|
| Hopper Jonathan Mark |
Chief Medical Officer |
• – – |
2021-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,625 |
25,371 |
|
- |
|
| Colangelo Dominick |
President and CEO |
• • – |
2021-02-11 |
4 |
D |
$49.23 |
$160,834 |
D/D |
(3,267) |
219,195 |
|
- |
|
| Colangelo Dominick |
President and CEO |
• • – |
2021-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
222,462 |
|
- |
|
| Hopper Jonathan Mark |
Chief Medical Officer |
• – – |
2021-02-06 |
4 |
D |
$47.18 |
$12,456 |
D/D |
(264) |
23,746 |
|
- |
|
| Hopper Jonathan Mark |
Chief Medical Officer |
• – – |
2021-02-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
650 |
24,010 |
|
- |
|
| Halpin Michael |
Chief Operating Officer |
• – – |
2021-02-06 |
4 |
D |
$47.18 |
$42,085 |
D/D |
(892) |
3,453 |
|
- |
|
| Halpin Michael |
Chief Operating Officer |
• – – |
2021-02-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,875 |
4,345 |
|
- |
|
| Colangelo Dominick |
President and CEO |
• • – |
2021-02-06 |
4 |
D |
$47.18 |
$145,220 |
D/D |
(3,078) |
214,962 |
|
- |
|
| Colangelo Dominick |
President and CEO |
• • – |
2021-02-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,938 |
218,040 |
|
- |
|
| Halpin Michael |
Chief Operating Officer |
• – – |
2020-12-21 |
4 |
AS |
$26.28 |
$788,400 |
D/D |
(30,000) |
2,279 |
|
125% |
|
| Halpin Michael |
Chief Operating Officer |
• – – |
2020-12-21 |
4 |
OE |
$2.65 |
$79,500 |
D/D |
30,000 |
32,279 |
|
- |
|
| Hopper Jonathan Mark |
Chief Medical Officer |
• – – |
2020-12-21 |
4 |
AS |
$26.27 |
$643,159 |
D/D |
(24,235) |
23,360 |
|
125% |
|
| Hopper Jonathan Mark |
Chief Medical Officer |
• – – |
2020-12-21 |
4 |
OE |
$10.95 |
$473,741 |
D/D |
43,264 |
35,069 |
|
- |
|
| Zerbe Robert L Md |
|
– • – |
2020-11-23 |
4 |
S |
$23.55 |
$412,125 |
D/D |
(17,500) |
31,795 |
|
-137% |
|
| Zerbe Robert L Md |
|
– • – |
2020-11-23 |
4 |
OE |
$2.76 |
$97,500 |
D/D |
30,000 |
49,295 |
|
- |
|
| Pennell Sandra |
VP and Corporate Controller |
• – – |
2020-09-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,440 |
|
160% |
|
| Halpin Michael |
Chief Operating Officer |
• – – |
2020-06-23 |
4 |
AS |
$15.01 |
$221,413 |
D/D |
(14,751) |
1,622 |
|
41% |
|
| Halpin Michael |
Chief Operating Officer |
• – – |
2020-06-23 |
4 |
OE |
$7.20 |
$106,207 |
D/D |
14,751 |
16,373 |
|
- |
|
| Halpin Michael |
Chief Operating Officer |
• – – |
2020-06-16 |
4 |
AS |
$15.00 |
$60,030 |
D/D |
(4,002) |
1,622 |
|
38% |
|
| Halpin Michael |
Chief Operating Officer |
• – – |
2020-06-16 |
4 |
OE |
$2.65 |
$7,659 |
D/D |
2,890 |
5,624 |
|
- |
|
| Colangelo Dominick |
President and CEO |
• • – |
2020-05-08 |
4 |
OE |
$2.75 |
$36,094 |
D/D |
13,125 |
210,492 |
|
- |
|
| Rubino Alan L |
|
– • – |
2020-04-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,750 |
2,644 |
|
- |
|
303 Records found
|
|
Page 9 of 13 |
|
|
0.55 (1.13%) 
